Monitoring iron overload disorder in MDS

Many patients with myelodysplastic syndromes (MDS) require regular red blood cell (RBC) transfusions to alleviate anemia-related symptoms as part of their supportive care.¹ Ineffective erythropoiesis results in the dysregulation of iron metabolism. Additionally, dependence on RBC transfusions can result in patients being unable to excrete the excess iron transfused, leading to iron overload.¹ While transfusion dependence is an independent negative prognostic factor, the resulting iron overload may also result in damage to DNA, cells, and organs due to oxidative stress.^1,2

Plasma ferritin levels are assessed in order to monitor iron overload, with ferritin levels >1,000 μg/L indicating iron overload.¹ Once these levels are reached, and the patient has received >20 RBC transfusions or is transfusion dependent, international guidelines recommend initiating iron chelation therapy (ICT) to remove excess iron from the body.¹ However, ferritin level assessment may be distorted by underlying inflammation and no longer correlate with iron availability. Monitoring transferrin saturation (TSAT) may give a better correlation with clinical outcomes in patients with MDS, but this has not been well studied.²

As part of our editorial theme on supportive care in MDS, we summarize two recently published articles by Rozema et al.¹ in the European Journal of Haematology and by Teichman et al.² in Haematologica, which discuss iron overload disorder in patients with MDS.

Monitoring ferritin levels – Rozema et al.¹

Methods

This study contained a retrospective cohort of 237 patients with MDS who received at least one RBC transfusion between 2005 and 2019 in Friesland, the Netherlands, from the HemoBase registry. Plasma ferritin was measured using a chemistry analyzer immunoassay. The revised International Prognostic Scoring System (IPSS-R) score, Charlson Comorbidity Index (CCI) score, and patient age were assessed to determine their contribution to plasma ferritin monitoring. Guideline adherence for initiating ICT was analyzed by comparing the prescription of ICT to national guidelines. The relative risks (RR) of monitoring plasma ferritin levels for different patient characteristics were analyzed using logistic regression analyses.

Results

Patient characteristics

Among the 237 patients identified, 69.2% were male with a median age of 76.0 years (Table 1). The median follow-up time for patients who received 1–20 RBC transfusions and >20 RBC transfusions was 18.2 months and 23.8 months, respectively. Patients were also categorized by MDS subtype (Figure 1).

Table 1. Patient characteristics*

Figure 1. MDS subtype by treatment received* 

del(5q), deletion in the long arm of Chromosome 5; EB, excess blasts; MDS, myelodysplastic syndromes; MLD, multilineage dysplasia; NOS, not otherwise specified; RBC, red blood cell; RS, ring sideroblasts; SLD, single lineage dysplasia.
*Data from Rozema, et al.¹

Plasma ferritin monitoring

Overall, 121 patients received >20 RBC transfusions. Of these patients, 47.1% had plasma ferritin measurements taken (Figure 2). There was a median of two measurements per patient. Plasma ferritin levels were >1,000 μg/L for 82.5% of patients who had >20 RBC transfusions and plasma ferritin measured.

Figure 2. Plasma ferritin measurements in patients who received >20 transfusions* 

RBC, red blood cell.
*Adapted from Rozema, et al.¹ 

Relative risk analysis

The RR analysis showed that, in patients with >20 transfusions, age, CCI scores, and IPSS-R scores did not significantly impact the probability of measuring plasma ferritin levels between the 15th and 25th RBC transfusion. Clinical performance was significantly associated with an increased probability of monitoring plasma ferritin levels between the 15th and 25th RBC transfusion, indicating that ferritin monitoring was primarily based on patients’ clinical performance instead of guideline recommendations. For patients who received >20 RBC transfusions, clinical performance was also significantly associated with an increased probability of monitoring plasma ferritin.

Iron chelation therapy

In this cohort, 47.3% of patients fulfilled the criteria for ICT; however, only 22.3% of these patients initiated ICT. A further 2.1% of the overall population received ICT despite not fulfilling the criteria. Plasma ferritin levels were monitored during ICT in 60% of patients. In 13.3% of the patients who received ICT, plasma ferritin was never measured. Univariate analyses showed no significant difference in gender, hospital type, and CCI score; however age <80 years and lower-risk IPSS-R were significantly associated with an increased probability of initiating ICT. Patients with good clinical performance were more likely to receive ICT than patients with poor clinical performance (Table 2).

Table 2. Relative risks of initiating ICT*

TSAT measurement – Teichman et al.²

Methods

This prospective observational study included 718 patients with MDS, chronic myelomonocytic leukemia (CMML), and low blast count acute myeloid leukemia (AML) with MDS-related changes registered to the Canadian National MDS registry within 1 year of diagnosis over an 11.5-year period. Mean values of ferritin and TSAT were calculated every 6 months. Median transfusion dose density (TDD) was calculated for patients at Year 1 with low- and high-TDD defined as below or above the median.

Results

Patient characteristics

The median age was 74 years. Of the 718 patients, 67% were IPSS-R very low, low, or intermediate (Table 3). Median follow-up time was 2.1 years. Patients were also stratified by MDS subtype (Figure 3).

Table 3. Patient characteristics*